Deep Expertise in Chemistry and Structure-based Drug Design Drives Pipeline of Highly Selective Compounds
At Kinnate, we specialize in developing innovative cancer treatments by targeting specific proteins called kinases. Kinase inhibition has been proven effective in fighting cancer for nearly 20 years, and we have a skilled team dedicated to discovering new drugs and advancing them to clinical trials.
Our approach focuses on creating unique programs that specifically target validated drivers of cancer. When designing our molecules, we prioritize four key factors: high selectivity (to minimize off target activity), optimized pharmaceutical properties (ensuring the drug works well in the body), broad coverage of genetic alterations (addressing different genetic changes in cancer cells), and the ability to overcome resistance or penetrate the brain.
Our goal is to develop drug candidates that have a therapeutic window, meaning they provide lasting and meaningful clinical responses to help patients. We focus on three specific patient populations:
- Patients with cancers that have known genetic drivers but currently lack targeted therapies.
- Patients with tumors that are well-characterized genetically and have intrinsic resistance to existing treatments.
- Patients whose tumors develop resistance to current therapies over time.
By focusing on these well-defined patient populations, we believe we can streamline the development process and increase our chances of success. We have built strong relationships with precision medicine cancer centers and research institutions, allowing us to leverage advancements in genomic profiling and deepen our understanding of specific cancer drivers.
Everyone at Kinnate is deeply committed to making a difference in the lives of patients with cancer by developing effective and targeted treatments based on cutting-edge research and collaboration with leading experts in the field.
A Focused Pipeline
We have developed a proprietary portfolio of small molecule candidates targeting validated drivers of cancer.
RAF / exarafenib Monotherapy
BRAF-Driven Advanced Adult Solid Tumors
RAF / exarafenib Combination
Advanced NRAS Mutant Melanoma
Exarafenib (KIN-2787) is an orally administered, potent and selective investigational small molecule pan-RAF inhibitor. Unlike currently available treatments that target only Class I BRAF kinase mutations, exarafenib is designed to target BRAF Class II and Class III alterations, where it has the potential to be a first-line targeted therapy, in addition to covering BRAF Class I alterations, and as a potential treatment for NRAS mutation-positive melanoma. KN-8701 is an ongoing, global Phase 1 clinical trial (NCT04913285) evaluating exarafenib in patients with advanced solid tumors harboring BRAF Class I, II and III alterations, and/or who have NRAS mutant melanoma. KN-8701 contains a two-part dose escalation: Part A1 is evaluating exarafenib as a monotherapy across BRAF alterations and tumor types, and Part A2 is evaluating exarafenib in combination with binimetinib, a MEK inhibitor. Part B, dose expansion, is evaluating exarafenib at the recommended dose and schedule in patients with BRAF-altered cancers including lung cancer, melanoma and other solid tumors1.
FGFR2/3 / KIN-3248
Naïve + Pre-treated FGFR2/3 Driven Advanced Adult Solid Tumors
c-Met-Driven Advanced Adult Solid Tumors
c-MET, Covers Acquired Resistance
Adult Solid Tumors